NCT Number: NCT07491471
Youth with public insurance underutilize diabetes care, particularly diabetes technology which is associated with improvement in diabetes-specific outcomes. Thus, we urgently need studies to understand and increase diabetes technology utilization. This proposed research will (1) address the gap in knowledge of barriers and promoters in youth working with clinicians to identify and address factors associated with diabetes technology uptake and utilization.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
As diabetes technologies have become more innovative and effective in the management of pediatric type 1 diabetes (T1D), research and usage has not engaged all youth living with T1D . Studies have consistently demonstrated lower rates of diabetes technology use in some youth. Although diabetes technology has the potential to improve in pediatric T1D outcomes. This proposal aims to build an evidence base for data-driven interventions designed to increase uptake and utilization of diabetes innovations by addressing barriers and supporting promoters of diabetes technology use. Focusing on clinicians, the overall objective of this proposal is to test a brief pilot intervention to increase provider recommendation of diabetes technology.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The design for this phase is a prospective pilot study. The intervention modules will be delivered weekly over a four-week period and will include pre- and post-intervention assessments of survey measurements. We will recruit 20 clinicians to participate in the delivery of the pilot intervention.
Time frame: Within 4 weeks upon intervention completion
The investigators will ask clincians questions in a 30-minute interview at the end of the four-week intervention. The investigators will evaluate feedback on ways the intervention could be more effective and what changes can be made to the intervention so that it is most effective. The investigators will ask clinicians if you they likely to change diabetes management after completing the intervention.
Time frame: Within 4 weeks upon intervention completion
The investigators will ask clincians questions in a feedback survey at the end of the four-week intervention. These questions will be developed by the investigators and will ask ways the intervention could be more effective and what changes can be made to the intervention so that it is most effective. Example questions of what the investigators plan to ask in the survey include: - Was the study explained appropriately? - Was it logistically easy to participate in the study? How could it have improved? - What parts of the intervention were most helpful? - What parts could be cut? - What parts need to be added? - Are there certain types of people who are likely to do better with this intervention?
Time frame: Through study completion, an average of one year
The investigators will also keep track of who enrolled in the study and track how many people completed the intervention.
Time frame: Within 4 weeks upon intervention completion
The investigators will ask you survey questions to understand clinician attitudes towards diabetes technology at the start and end of the study intervention. The investigators will use a validated survey measure called Diabetes Technology Attitudes Survey to assess this in addition to having conversations with clinicians to learn beliefs about diabetes technology.
Stanford University
Other
Improving Outcomes in Pediatric Diabetes: Building the Evidence Base to Inform Effective Diabetes Technology Interventions
Acronym: BEAD-T1D
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07282639
Autoimmune Diseases, Diabetes Mellitus
Los Angeles, California, United States
View Trial DetailsNCT07616206
Autoimmune Diseases, Diabetes Mellitus
Atlanta, Georgia, United States
View Trial DetailsNCT07828626
Autoimmune Diseases, Diabetes
Truro, Cornwall, United Kingdom
View Trial DetailsNCT07699380
Autoimmune Diseases, Combination Therapy
Seattle, Washington, United States
View Trial Details